Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 June 2018Published: 23 March 2011
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 23 July 2025
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 23 July 2025
Gantenerumab for treating early Alzheimer's disease [TSID10668]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Alzheimer's disease (early) - gantenerumab [ID6142]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pridopidine for treating Huntington's disease [ID6525]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [TSID12157]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC